GGrantIndex
Sort

48,018 grants matching immunotherapy

PHASE I/II TRIAL OF HOKT3(1(ALA-ALA) IN TYPE 1 DIABETES

$515,514
Columbia University Health Sciences · R01 · FY2003 · DK

Role of Tspan5 in MHC I antigen presentation and cancer immune evasion

$515,375
Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · AI

eDyNAmiC-TEXASSW

$515,342
Zhijian J Chen · Ut Southwestern Medical Center · OT2 · FY2025 · CA

Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer

$515,333
Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2024 · CA

CAREER: A Biomanufactured Platform for Modulating Immune Cell-Bacteria Interactions in the Tumor Microenvironment

$515,223
Bahareh Behkam · Virginia Polytechnic Institute And State University · · FY2015 · ENG

Regulatory and effector T cells in oral immunotherapy for food allergy

$515,197
Wayne G Shreffler · Massachusetts General Hospital · U19 · FY2014 · AI

Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells

$515,180
Christopher A Pennell · University Of Minnesota · R01 · FY2024 · CA

Hydrogen sulfide functions as a tumor suppressor in glioblastoma

$515,147
Christopher Michael Hine · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS

Hydrogen sulfide functions as a tumor suppressor in glioblastoma

$515,147
Christopher Michael Hine · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · NS

Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer

$515,141
Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Targeting the gut microbiome to inhibit melanoma lymph node metastases

$515,112
Jennifer A. Wargo · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Development of FISH Molecular Diagnostics to support Clinical Trials at NCI

$515,103
Svetlana Pack · Division Of Basic Sciences - Nci · ZID · FY2013 · CA

Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer

$515,091
Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Project 2: The Impact of Immunotherapy on Human Vaccination

$515,006
E. John Wherry · Massachusetts General Hospital · U19 · FY2020 · AI

New Materials to Deliver mRNA: Applications in Cancer Immunotherapy

$514,997
Robert M. Waymouth · Stanford University · R01 · FY2023 · CA

Core--Specimen

$514,995
Nancy B. Kiviat · Fred Hutchinson Cancer Research Center · P50 · FY2007 · CA

Host-Tumor Cell Interactions in Myeloma: Therapeutic Applications

$514,934
Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2009 · CA

Manipulating normal estrogen physiology as a therapeutic approach in cancer

$514,902
Donald P McDonnell · Duke University · R01 · FY2024 · CA

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) - DCC

$514,831
Susanne May · University Of Washington · U01 · FY2017 · HL

Mechanisms of T Cell Memory Quiescence

$514,790
Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2021 · AI

Mechanisms of T Cell Memory Quiescence

$514,790
Surojit Sarkar · Seattle Children'S Hospital · R01 · FY2022 · AI

Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation

$514,741
Benjamin G Vincent · Univ Of North Carolina Chapel Hill · R37 · FY2023 · CA

Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer

$514,697
Zihai Li · Cedars-Sinai Medical Center · P01 · FY2025 · CA

Lymph node-targeted multistage chemoimmunotherapy for lymphoma

$514,622
Susan Napier Thomas · Georgia Institute Of Technology · R01 · FY2021 · CA

Effector T Cell Trafficking in Ovarian Cancer

$514,525
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2015 · CA